NASDAQ:GILD - Gilead Sciences Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $79.36
  • Forecasted Upside: 10.58 %
  • Number of Analysts: 14
  • Breakdown:
  • 0 Sell Ratings
  • 6 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.11 (-0.15%)

This chart shows the closing price for GILD by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Gilead Sciences Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GILD and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GILD

Analyst Price Target is $79.36
▲ +10.58% Upside Potential
This price target is based on 14 analysts offering 12 month price targets for Gilead Sciences in the last 3 months. The average price target is $79.36, with a high forecast of $100.00 and a low forecast of $66.00. The average price target represents a 10.58% upside from the last price of $71.77.

This chart shows the closing price for GILD for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 14 polled investment analysts is to buy stock in Gilead Sciences. This rating has held steady since April 2021, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 13 buy ratings
  • 13 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 13 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 13 buy ratings
  • 13 hold ratings
  • 2 sell ratings
  • 0 strong buy ratings
  • 12 buy ratings
  • 10 hold ratings
  • 1 sell ratings
  • 0 strong buy ratings
  • 10 buy ratings
  • 10 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 8 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 9 buy ratings
  • 6 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 6 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
1/14/2022BMO Capital MarketsInitiated CoverageBuy$85.00Low
1/6/2022Morgan StanleyDowngradeOverweight ➝ Equal Weight$84.00 ➝ $74.00Low
12/15/2021BMO Capital MarketsReiterated RatingBuyMedium
12/14/2021SVB LeerinkReiterated RatingBuyMedium
12/8/2021Wells Fargo & CompanyInitiated CoverageEqual Weight$72.00Medium
12/6/2021The Goldman Sachs GroupInitiated CoverageNeutral$80.00Low
11/19/2021Piper SandlerInitiated CoverageNeutral$77.00Medium
11/18/2021BMO Capital MarketsUpgradeMarket Perform ➝ Outperform$72.00 ➝ $85.00Medium
10/31/2021Evercore ISIReiterated RatingBuyMedium
10/29/2021SVB LeerinkLower Price TargetOutperform$77.00 ➝ $75.00High
10/12/2021Morgan StanleyBoost Price TargetOverweight$83.00 ➝ $84.00Medium
8/27/2021Morgan StanleyReiterated RatingBuy$83.00Low
8/23/2021Royal Bank of CanadaReiterated RatingBuyC$84.00Low
7/30/2021SVB LeerinkBoost Price TargetOutperform$74.00 ➝ $77.00Low
7/30/2021BMO Capital MarketsBoost Price TargetMarket Perform$67.00 ➝ $72.00Low
7/30/2021Royal Bank of CanadaBoost Price TargetOutperform$81.00 ➝ $84.00Medium
6/28/2021OppenheimerInitiated CoverageBuy$100.00Low
5/7/2021Jefferies Financial GroupReiterated RatingBuy$80.00Low
5/3/2021Morgan StanleyBoost Price TargetOverweight$81.00 ➝ $83.00High
4/30/2021SVB LeerinkBoost Price TargetOutperform$72.00 ➝ $74.00Medium
4/30/2021Needham & Company LLCReiterated RatingHoldHigh
4/19/2021Morgan StanleyLower Price TargetOverweight$87.00 ➝ $81.00Low
4/1/2021Sanford C. BernsteinUpgradeMarket Perform ➝ Outperform$80.00Medium
3/30/2021Redburn PartnersUpgradeNeutral ➝ BuyLow
2/11/2021SVB LeerinkLower Price TargetOutperform$73.00 ➝ $72.00Low
2/5/2021SVB LeerinkLower Price TargetOutperform$74.00 ➝ $73.00High
2/5/2021Credit Suisse GroupBoost Price TargetNeutral$65.00 ➝ $66.00High
2/5/2021Morgan StanleyBoost Price TargetOverweight$83.00 ➝ $87.00High
1/19/2021Morgan StanleyUpgradeEqual Weight ➝ Overweight$83.00High
1/4/2021GuggenheimUpgradeNeutral ➝ BuyN/A
12/22/2020Smith Barney CitigroupLower Price Target$75.00 ➝ $72.00Low
12/18/2020Truist FinancialLower Price Target$67.00 ➝ $625.00High
12/17/2020OppenheimerLower Price TargetOutperform$105.00 ➝ $100.00Low
12/16/2020BMO Capital MarketsLower Price TargetMarket Perform$64.00 ➝ $62.00Low
12/16/2020Credit Suisse GroupLower Price TargetNeutral$70.00 ➝ $65.00Low
12/16/2020Robert W. BairdBoost Price TargetNeutral$63.00 ➝ $67.00Low
12/15/2020Piper SandlerLower Price TargetOverweight$84.00 ➝ $80.00Low
12/14/2020Redburn PartnersInitiated CoverageNeutralLow
12/8/2020JPMorgan Chase & Co.Reiterated RatingHoldLow
11/3/2020Morgan StanleyReiterated RatingEqual Weight$67.00Low
10/29/2020Cantor FitzgeraldReiterated RatingOverweight$84.00 ➝ $86.00Medium
10/29/2020BMO Capital MarketsLower Price TargetMarket Perform$74.00 ➝ $64.00Medium
10/29/2020BarclaysLower Price Target$67.00 ➝ $62.00Medium
10/29/2020Wells Fargo & CompanyLower Price TargetEqual Weight$69.00 ➝ $63.00Low
10/29/2020Piper SandlerLower Price TargetOverweight$95.00 ➝ $84.00Medium
10/29/2020SVB LeerinkLower Price TargetOutperform$88.00 ➝ $79.00Low
10/28/2020UBS GroupInitiated CoverageNeutral$61.00Medium
9/30/2020Jefferies Financial GroupInitiated CoverageBuy$78.00Low
9/18/2020Royal Bank of CanadaBoost Price Target$82.00 ➝ $86.00Low
9/15/2020Royal Bank of CanadaLower Price TargetOutperform$84.00 ➝ $82.00Low
9/15/2020Maxim GroupUpgradeHold ➝ Buy$88.00Low
9/14/2020SVB LeerinkLower Price TargetOutperform$94.00 ➝ $88.00High
9/14/2020Raymond JamesReiterated RatingHoldHigh
9/10/2020OppenheimerBoost Price TargetOutperform$90.00 ➝ $105.00Medium
8/20/2020TruistLower Price Target$74.00 ➝ $67.00Low
8/19/2020Piper SandlerLower Price TargetOverweight$85.00 ➝ $83.00Medium
8/19/2020Jefferies Financial GroupLower Price Target$97.00 ➝ $78.00Medium
8/19/2020Wells Fargo & CompanyBoost Price TargetEqual Weight$69.00 ➝ $76.00High
8/19/2020BMO Capital MarketsBoost Price TargetMarket Perform$74.00 ➝ $79.00Medium
8/19/2020Cantor FitzgeraldLower Price TargetOverweight$86.00 ➝ $84.00Medium
8/7/2020JPMorgan Chase & Co.Reiterated RatingHoldLow
8/3/2020CitigroupBoost Price Target$78.00 ➝ $80.00Low
7/31/2020SVB LeerinkReiterated RatingBuy$95.00High
7/31/2020Cantor FitzgeraldReiterated RatingBuy$86.00High
7/31/2020Piper SandlerLower Price TargetOverweight$90.00 ➝ $85.00Medium
7/31/2020Credit Suisse GroupLower Price TargetNeutral$75.00 ➝ $73.00Medium
7/31/2020SunTrust BanksBoost Price TargetHold$73.00 ➝ $74.00Medium
7/31/2020Royal Bank of CanadaLower Price TargetOutperform$89.00 ➝ $87.00Medium
7/31/2020Morgan StanleyLower Price TargetEqual Weight$80.00 ➝ $79.00Medium
7/31/2020Wells Fargo & CompanyLower Price TargetEqual Weight$87.00 ➝ $76.00Medium
7/28/2020JPMorgan Chase & Co.Reiterated RatingHold$85.00Low
7/21/2020Jefferies Financial GroupReiterated RatingBuy$97.00Low
7/20/2020Credit Suisse GroupUpgradeUnderperform ➝ Neutral$64.00 ➝ $75.00Low
7/15/2020Morgan StanleyBoost Price TargetEqual Weight$77.00 ➝ $80.00Low
7/6/2020Royal Bank of CanadaReiterated RatingBuyLow
6/30/2020Needham & Company LLCReiterated RatingHoldHigh
6/29/2020Robert W. BairdReiterated RatingHold$76.00High
6/22/2020Jefferies Financial GroupReiterated RatingBuy$97.00Low
6/15/2020DZ BankReiterated RatingBuyMedium
6/8/2020Piper SandlerReiterated RatingBuy$90.00Low
6/3/2020Royal Bank of CanadaReiterated RatingBuy$88.00High
6/3/2020SVB LeerinkUpgradeMarket Perform ➝ Outperform$85.00 ➝ $94.00Low
6/2/2020Maxim GroupReiterated RatingHoldHigh
6/1/2020Needham & Company LLCReiterated RatingHoldHigh
5/26/2020SunTrust BanksUpgradeSell ➝ Hold$70.00 ➝ $73.00Medium
5/21/2020Piper SandlerReiterated RatingBuy$90.00Low
5/21/2020Robert W. BairdReiterated RatingHold$75.00Low
5/18/2020OppenheimerReiterated RatingBuyHigh
5/13/2020MizuhoReiterated RatingBuy$81.00Low
5/13/2020JPMorgan Chase & Co.Reiterated RatingHold$85.00High
5/5/2020Royal Bank of CanadaReiterated RatingBuy$88.00Low
5/1/2020Wells Fargo & CompanyReiterated RatingHold$84.00Low
5/1/2020SVB LeerinkBoost Price TargetMarket Perform$68.00 ➝ $85.00Low
5/1/2020OppenheimerBoost Price TargetOutperform$80.00 ➝ $90.00Low
5/1/2020Morgan StanleyBoost Price TargetEqual Weight$75.00 ➝ $77.00Low
5/1/2020Raymond JamesDowngradeOutperform ➝ Market PerformLow
5/1/2020SunTrust BanksDowngradeHold ➝ Sell$70.00Low
5/1/2020JPMorgan Chase & Co.DowngradeOverweight ➝ NeutralLow
4/30/2020Maxim GroupReiterated RatingHoldHigh
4/29/2020OppenheimerInitiated CoverageBuy$80.00Medium
4/29/2020Robert W. BairdReiterated RatingHold$76.00Medium
4/29/2020CfraBoost Price TargetSell$71.00 ➝ $74.00Medium
4/29/2020MizuhoReiterated RatingBuy$81.00Low
4/27/2020UBS GroupDowngradeBuy ➝ Neutral$77.00 ➝ $80.00Low
4/23/2020Royal Bank of CanadaReiterated RatingBuy$85.00Low
4/23/2020MizuhoInitiated CoverageBuy$81.00Low
4/23/2020Raymond JamesReiterated RatingBuy$80.00Low
4/20/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$79.00Medium
4/20/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$87.00Medium
4/19/2020Needham & Company LLCReiterated RatingHoldHigh
4/18/2020Maxim GroupInitiated CoverageHoldHigh
4/17/2020Credit Suisse GroupReiterated RatingSell$60.00High
4/17/2020Royal Bank of CanadaReiterated RatingBuy$85.00High
4/17/2020JPMorgan Chase & Co.Reiterated RatingBuyHigh
4/17/2020CfraDowngradeHold ➝ SellHigh
4/16/2020Piper SandlerReiterated RatingBuy$90.00High
4/13/2020Jefferies Financial GroupReiterated RatingBuy$89.00High
4/13/2020CowenReiterated RatingBuy$80.00High
4/13/2020BMO Capital MarketsReiterated RatingOutperform ➝ Buy$79.00High
4/13/2020Needham & Company LLCReiterated RatingHoldLow
4/7/2020Cantor FitzgeraldBoost Price TargetOverweight$78.00 ➝ $86.00High
4/6/2020Credit Suisse GroupReiterated RatingSell$60.00High
3/31/2020Wolfe ResearchInitiated CoverageMarket Perform$65.00Low
3/30/2020SVB LeerinkReiterated RatingHold$68.00Low
3/25/2020Royal Bank of CanadaReiterated RatingBuy$83.00High
3/25/2020SunTrust BanksReiterated RatingHoldHigh
3/20/2020Piper SandlerUpgradeNeutral ➝ Overweight$70.00 ➝ $90.00High
3/18/2020Royal Bank of CanadaReiterated RatingBuy$83.00High
3/18/2020DZ BankUpgradeHold ➝ Buy$80.00High
3/9/2020Royal Bank of CanadaDowngradeTop Pick ➝ Outperform$86.00High
3/4/2020Wells Fargo & CompanyBoost Price TargetOverweight$81.00 ➝ $87.00Low
3/3/2020Credit Suisse GroupReiterated RatingUnderperformLow
3/2/2020MizuhoInitiated CoverageBuy$81.00Low
3/2/2020HC WainwrightDowngradeBuy ➝ NeutralHigh
2/28/2020DZ BankDowngradeBuy ➝ Hold$80.00High
2/27/2020BarclaysInitiated CoverageUnderweight$62.00High
2/24/2020SunTrust BanksReiterated RatingHold$70.00High
2/19/2020Royal Bank of CanadaReiterated RatingBuy$86.00Low
2/9/2020Maxim GroupReiterated RatingHoldLow
2/6/2020Sanford C. BernsteinDowngradeOutperform ➝ Market Perform$78.00 ➝ $70.00High
2/5/2020Piper SandlerLower Price Target$75.00 ➝ $70.00High
2/5/2020Bank of AmericaBoost Price TargetNeutral$70.00 ➝ $72.00Low
2/5/2020Credit Suisse GroupBoost Price TargetUnderperform$59.00 ➝ $60.00Low
2/5/2020JPMorgan Chase & Co.Reiterated RatingBuyMedium
2/5/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$81.00 ➝ $80.00Medium
1/21/2020GuggenheimDowngradeBuy ➝ NeutralLow
1/3/2020OppenheimerUpgradeMarket Perform ➝ OutperformLow
1/2/2020CowenReiterated RatingBuy$85.00Low
12/13/2019Credit Suisse GroupDowngradeNeutral ➝ Underperform$67.00 ➝ $63.00High
11/12/2019SunTrust BanksInitiated CoverageHold$70.00Low
10/25/2019GuggenheimSet Price TargetBuy$86.00High
10/25/2019Wells Fargo & CompanySet Price TargetBuy$81.00N/A
10/25/2019Robert W. BairdSet Price TargetHold$76.00N/A
10/25/2019Morgan StanleySet Price TargetHold$75.00N/A
10/25/2019OppenheimerLower Price TargetOutperform$85.00 ➝ $80.00Low
10/25/2019Maxim GroupDowngradeBuy ➝ HoldHigh
10/25/2019Cantor FitzgeraldLower Price TargetOverweight$88.00 ➝ $85.00High
10/16/2019Bank of AmericaInitiated CoverageNeutral$70.00Low
10/15/2019MizuhoSet Price TargetBuy$81.00Low
8/23/2019Raymond JamesSet Price TargetBuy$85.00Low
7/31/2019BMO Capital MarketsSet Price TargetBuy$82.00Low
7/31/2019CitigroupSet Price TargetBuy$78.00Low
7/31/2019Maxim GroupSet Price TargetBuy$84.00N/A
7/31/2019Credit Suisse GroupLower Price TargetNeutral$70.00 ➝ $67.00Medium
7/31/2019JPMorgan Chase & Co.Reiterated RatingBuy$85.00High
7/31/2019Raymond JamesBoost Price TargetStrong-Buy$83.00 ➝ $86.00High
7/29/2019Royal Bank of CanadaUpgradeOutperform ➝ Top Pick$91.00Low
7/15/2019Needham & Company LLCReiterated RatingHoldLow
7/15/2019Jefferies Financial GroupSet Price TargetBuy$95.00Low
7/15/2019MizuhoSet Price TargetBuy$88.00Low
7/15/2019Morgan StanleySet Price TargetHold$82.00Low
7/15/2019Cantor FitzgeraldSet Price TargetBuy$88.00Low
7/15/2019BMO Capital MarketsSet Price TargetBuy$76.00Low
7/15/2019Maxim GroupSet Price TargetBuy$84.00Low
7/15/2019Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$68.00 ➝ $88.00High
7/12/2019OppenheimerSet Price TargetBuy$85.00High
7/2/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
6/19/2019MizuhoReiterated RatingBuy$88.00Low
5/28/2019The Goldman Sachs GroupDowngradeNeutral ➝ Sell$70.00 ➝ $60.00High
5/22/2019CitigroupUpgradeNeutral ➝ Buy$66.80Low
5/20/2019Credit Suisse GroupInitiated CoverageNeutral$70.00Low
5/17/2019MizuhoSet Price TargetBuy$88.00Low
5/17/2019Evercore ISIReiterated RatingBuyLow
5/10/2019MizuhoSet Price TargetBuy$88.00High
5/7/2019JPMorgan Chase & Co.Reiterated RatingBuy$87.00Low
5/6/2019Needham & Company LLCReiterated RatingHoldHigh
5/3/2019Raymond JamesSet Price TargetBuy$83.00Low
5/3/2019CowenReiterated RatingBuyHigh
4/28/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
4/26/2019Sanford C. BernsteinInitiated CoverageOutperform ➝ Outperform$82.00Medium
4/25/2019Cantor FitzgeraldReiterated RatingBuy$87.00Low
4/23/2019Raymond JamesSet Price TargetBuy$86.00Low
4/22/2019OppenheimerSet Price TargetBuy$85.00Low
4/22/2019MizuhoSet Price TargetBuy$88.00Low
4/12/2019MizuhoSet Price TargetBuy$88.00Low
4/10/2019UBS GroupUpgradeNeutral ➝ Buy$75.00 ➝ $77.00Low
3/29/2019Maxim GroupReiterated RatingBuy$84.00Medium
3/22/2019MizuhoSet Price TargetBuy$88.00Low
3/19/2019OppenheimerSet Price TargetBuy$85.00Medium
3/14/2019BMO Capital MarketsInitiated CoverageOutperform$78.00Medium
3/7/2019Piper Jaffray CompaniesSet Price TargetHold$75.00Medium
3/7/2019JPMorgan Chase & Co.Reiterated RatingBuyLow
2/26/2019MizuhoReiterated RatingBuy$88.00Low
2/12/2019Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$90.00 ➝ $85.00Low
2/12/2019CitigroupDowngradeBuy ➝ Neutral$100.00 ➝ $75.00Medium
2/11/2019Wells Fargo & CompanyDowngradeOutperform ➝ Market Perform$95.00 ➝ $68.00Medium
2/5/2019Maxim GroupSet Price TargetBuy$84.00Medium
2/5/2019Raymond JamesSet Price TargetBuy$90.00Medium
2/5/2019Wells Fargo & CompanyLower Price TargetOutperform$95.00 ➝ $89.00Low
2/5/2019CitigroupReiterated RatingBuy$100.00Low
1/3/2019CIBCUpgradeMarket Perform ➝ Outperform$85.00Low
1/3/2019OppenheimerUpgradeMarket Perform ➝ Outperform$85.00High
12/20/2018Raymond JamesSet Price TargetBuy$94.00High
12/19/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$85.00 ➝ $86.00Medium
12/19/2018Cantor FitzgeraldReiterated RatingOverweight$92.00Medium
12/17/2018GuggenheimInitiated CoverageBuy$86.00Low
11/14/2018OppenheimerReiterated RatingHoldMedium
11/14/2018Needham & Company LLCReiterated RatingHoldMedium
11/1/2018Raymond JamesReiterated RatingBuyLow
11/1/2018MizuhoSet Price TargetBuy$94.00Medium
10/31/2018Evercore ISIReiterated RatingBuyMedium
10/26/2018MizuhoSet Price TargetBuy$94.00High
10/26/2018Raymond JamesLower Price TargetStrong-Buy ➝ Strong-Buy$97.00 ➝ $94.00Low
10/26/2018BarclaysBoost Price TargetOverweight ➝ Overweight$90.00 ➝ $95.00Medium
10/26/2018Piper Jaffray CompaniesDowngradeOverweight ➝ Neutral$85.00 ➝ $75.00High
10/26/2018Cantor FitzgeraldBoost Price TargetOverweight ➝ Overweight$87.00 ➝ $88.00Medium
10/1/2018Cantor FitzgeraldInitiated CoverageOverweight ➝ Overweight$87.00Low
9/12/2018Piper Jaffray CompaniesSet Price TargetBuy$85.00Medium
8/10/2018MizuhoReiterated RatingBuy$94.00Low
7/31/2018MizuhoSet Price TargetBuy$94.00Low
7/26/2018Morgan StanleyBoost Price TargetEqual Weight ➝ Equal Weight$81.00 ➝ $85.00Medium
7/26/2018Wells Fargo & CompanyBoost Price TargetOutperform$89.00 ➝ $95.00High
7/26/2018Robert W. BairdDowngradeOutperform ➝ Neutral$79.00High
6/28/2018Raymond JamesInitiated CoverageStrong-Buy$93.00Medium
5/30/2018Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Buy$85.00Medium
5/2/2018Needham & Company LLCReiterated RatingHoldHigh
5/2/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$85.00 ➝ $81.00Low
5/2/2018BarclaysLower Price TargetOverweight ➝ Buy$95.00 ➝ $90.00High
5/2/2018SVB LeerinkSet Price TargetMarket Perform$80.00 ➝ $72.00High
4/17/2018Credit Suisse GroupSet Price TargetHold$80.00Low
3/6/2018BarclaysReiterated RatingOverweight ➝ Overweight$90.00 ➝ $95.00Low
2/23/2018Royal Bank of CanadaReiterated RatingBuy$94.00Low
2/22/2018SVB LeerinkReiterated RatingMkt Perform ➝ Market Perform$83.00 ➝ $80.00Low
2/12/2018MizuhoReiterated RatingBuy ➝ Buy$83.00 ➝ $95.00Low
2/8/2018BMO Capital MarketsBoost Price TargetOutperform ➝ Market Perform$86.00 ➝ $88.00High
2/8/2018CitigroupReiterated RatingBuy ➝ Buy$103.00 ➝ $105.00High
2/7/2018Credit Suisse GroupSet Price TargetHold$80.00High
2/7/2018BMO Capital MarketsReiterated RatingHoldHigh
2/7/2018SVB LeerinkLower Price TargetMarket Perform ➝ Market Perform$86.00 ➝ $83.00Low
2/7/2018Morgan StanleyLower Price TargetEqual Weight ➝ Equal Weight$87.00 ➝ $84.00Medium
2/7/2018Bank of AmericaBoost Price TargetNeutral ➝ Neutral$82.00 ➝ $87.00Medium
2/6/2018Maxim GroupSet Price TargetBuy$94.00High
2/5/2018MizuhoSet Price TargetBuy$83.00 ➝ $95.00High
1/30/2018CitigroupUpgradeNeutral ➝ Buy$88.80 ➝ $76.00Low
1/26/2018Jefferies Financial GroupUpgradeHold ➝ Buy$81.19 ➝ $93.00High
1/16/2018Wells Fargo & CompanyUpgradeMarket Perform ➝ Outperform$79.02 ➝ $96.00Low
1/3/2018Credit Suisse GroupSet Price TargetHold$80.00Low
1/3/2018BMO Capital MarketsReiterated RatingHoldLow
12/21/2017OppenheimerReiterated RatingHoldMedium
12/20/2017Credit Suisse GroupDowngradeOutperform ➝ Neutral$74.35 ➝ $80.00Low
12/11/2017Maxim GroupSet Price TargetBuy$94.00Medium
12/7/2017Credit Suisse GroupReiterated RatingBuy$82.00Medium
11/30/2017Maxim GroupUpgradeHold ➝ Buy$73.67 ➝ $94.00Low
11/13/2017ArgusDowngradeBuy ➝ Hold$73.25 ➝ $73.77N/A
11/8/2017MizuhoBoost Price TargetBuy$77.00 ➝ $83.00N/A
10/29/2017MizuhoSet Price TargetBuy$77.00N/A
10/27/2017Maxim GroupReiterated RatingHoldN/A
10/27/2017BMO Capital MarketsLower Price TargetOutperform$89.00 ➝ $83.00N/A
10/25/2017JPMorgan Chase & Co.Set Price TargetBuy$85.00N/A
10/20/2017BMO Capital MarketsReiterated RatingHold$82.00N/A
10/19/2017Maxim GroupReiterated RatingHoldN/A
10/19/2017SVB LeerinkBoost Price TargetMarket Perform$84.00 ➝ $85.00N/A
10/19/2017William BlairReiterated RatingBuyN/A
10/19/2017Berenberg BankSet Price TargetBuy$96.00N/A
10/11/2017BarclaysReiterated RatingOverweight ➝ Overweight$90.00N/A
10/6/2017Morgan StanleyReiterated RatingEqual Weight$77.00 ➝ $83.00N/A
10/5/2017SVB LeerinkBoost Price TargetMarket Perform$87.00 ➝ $89.00N/A
10/5/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformN/A
10/5/2017OppenheimerInitiated CoverageMarket PerformN/A
10/5/2017Jefferies Financial GroupInitiated CoverageHold ➝ PositiveN/A
10/4/2017Bank of AmericaLower Price TargetNeutral$87.00 ➝ $86.00Low
10/4/2017Jefferies Financial GroupReiterated RatingHold ➝ Hold$93.00Low
9/29/2017MizuhoReiterated RatingBuyLow
9/20/2017SVB LeerinkReiterated RatingMarket Perform$82.00 ➝ $87.00Medium
9/14/2017Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$94.00Low
9/6/2017Berenberg BankReiterated RatingBuy$86.00 ➝ $96.00Low
9/6/2017Wells Fargo & CompanyBoost Price TargetMarket Perform$73.00 ➝ $81.00Low
8/31/2017CowenReiterated RatingOutperform$90.00Medium
8/31/2017Wells Fargo & CompanyReiterated RatingMarket Perform ➝ Market Perform$73.00 ➝ $81.00Medium
8/31/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$81.00Medium
8/31/2017William BlairReiterated RatingOutperform ➝ Outperform$87.00Low
8/31/2017ArgusUpgradeHold ➝ Buy$100.00High
8/29/2017Berenberg BankSet Price TargetBuy$86.00Low
8/29/2017Robert W. BairdReiterated RatingOutperform$87.00Low
8/29/2017Credit Suisse GroupReiterated RatingOutperform$79.00 ➝ $85.00Medium
8/28/2017Needham & Company LLCReiterated RatingHoldLow
8/28/2017Credit Suisse GroupSet Price TargetBuy$79.00High
8/28/2017Maxim GroupReiterated RatingHoldHigh
8/20/2017Berenberg BankReiterated RatingBuy$79.00 ➝ $86.00Low
7/27/2017CowenReiterated RatingOutperform$90.00Medium
7/27/2017Deutsche Bank AktiengesellschaftReiterated RatingBuy$79.00 ➝ $81.00Medium
7/27/2017BMO Capital MarketsReiterated RatingOutperform$72.00 ➝ $82.00Medium
7/27/2017Jefferies Financial GroupReiterated RatingHold$83.00Medium
7/27/2017Maxim GroupReiterated RatingHoldMedium
7/27/2017JPMorgan Chase & Co.Set Price TargetOverweight$80.00 ➝ $85.00Medium
7/26/2017Redburn PartnersInitiated CoverageBuyMedium
7/25/2017Robert W. BairdReiterated RatingOutperform$87.00Low
7/25/2017SVB LeerinkReiterated RatingHold$74.00Low
7/21/2017BMO Capital MarketsReiterated RatingHold$72.00Low
7/13/2017Robert W. BairdReiterated RatingOutperform$87.00Low
7/11/2017Morgan StanleyReiterated RatingEqual WeightLow
7/11/2017Jefferies Financial GroupReiterated RatingHold ➝ Hold$80.00Low
7/5/2017CowenReiterated RatingOutperform$90.00Low
7/4/2017JPMorgan Chase & Co.Reiterated RatingOverweight$82.00Low
7/4/2017Jefferies Financial GroupReiterated RatingBuy$82.00Low
6/23/2017Deutsche Bank AktiengesellschaftInitiated CoverageBuy$79.00Low
6/22/2017SVB LeerinkReiterated RatingMarket PerformLow
6/16/2017William BlairReiterated RatingOutperformLow
5/15/2017Credit Suisse GroupReiterated RatingOutperform$79.00N/A
5/5/2017Credit Suisse GroupReiterated RatingOutperform$79.00Low
5/3/2017GabelliReiterated RatingBuy$85.00Medium
5/3/2017BarclaysReiterated RatingOverweight$85.00Medium
5/3/2017Stifel NicolausReiterated RatingBuy$87.00Medium
5/3/2017Robert W. BairdReiterated RatingOutperform$87.00Medium
5/3/2017Maxim GroupReiterated RatingHoldLow
5/3/2017BMO Capital MarketsReiterated RatingHold$75.00 ➝ $76.00Low
4/26/2017William BlairReiterated RatingOutperformLow
4/24/2017Stifel NicolausReiterated RatingBuy$87.00Low
4/23/2017BarclaysReiterated RatingOverweight$90.00 ➝ $85.00Medium
4/21/2017Piper Jaffray CompaniesReiterated RatingBuyLow
4/21/2017Maxim GroupReiterated RatingHoldLow
4/17/2017CowenReiterated RatingBuy$100.00Low
4/6/2017Jefferies Financial GroupReiterated RatingBuy$82.00Low
4/6/2017JPMorgan Chase & Co.Reiterated RatingOverweight$82.00Low
3/22/2017Jefferies Financial GroupReiterated RatingBuyLow
3/22/2017BarclaysReiterated RatingBuy$90.00Low
3/15/2017Jefferies Financial GroupReiterated RatingBuy$63.00Low
3/15/2017Credit Suisse GroupReiterated RatingOutperform$79.00Low
3/13/2017Bank of AmericaReiterated RatingNeutral$76.00 ➝ $68.19Low
3/13/2017The Goldman Sachs GroupReiterated RatingNeutral$70.00 ➝ $68.00Low
3/11/2017BarclaysReiterated RatingOutperform$90.00N/A
3/9/2017UBS GroupReiterated RatingNeutral ➝ Neutral$118.00 ➝ $72.00N/A
3/1/2017MizuhoLower Price TargetBuy$88.00 ➝ $77.00N/A
3/1/2017Credit Suisse GroupReiterated RatingBuy$79.00N/A
2/16/2017Piper Jaffray CompaniesReiterated RatingOverweightN/A
2/14/2017Stifel NicolausSet Price TargetBuy$87.00N/A
2/14/2017JPMorgan Chase & Co.Set Price TargetBuy$82.00N/A
2/14/2017Berenberg BankSet Price TargetBuy$112.00 ➝ $78.00N/A
2/14/2017Jefferies Financial GroupReiterated RatingBuy$83.00N/A
2/9/2017BarclaysReiterated RatingBuyN/A
2/9/2017BMO Capital MarketsReiterated RatingHold$88.00 ➝ $75.00N/A
2/8/2017SVB LeerinkSet Price TargetHold$91.00 ➝ $74.00N/A
2/8/2017JPMorgan Chase & Co.Set Price TargetBuy$96.00 ➝ $82.00N/A
2/8/2017Royal Bank of CanadaLower Price Target$75.00N/A
2/8/2017Jefferies Financial GroupLower Price TargetBuy ➝ Neutral$83.00 ➝ $83.00N/A
2/8/2017Needham & Company LLCReiterated RatingHoldN/A
2/8/2017Piper Jaffray CompaniesReiterated RatingHold$102.00 ➝ $95.00N/A
2/8/2017Robert W. BairdReiterated RatingOutperform$87.00N/A
2/8/2017CitigroupDowngradeBuy ➝ Neutral$87.00 ➝ $76.00N/A
2/8/2017Morgan StanleyLower Price TargetEqual Weight$85.00 ➝ $77.00N/A
2/8/2017Wells Fargo & CompanyReiterated RatingMarket Perform$79.50 ➝ $65.50N/A
2/8/2017Credit Suisse GroupLower Price TargetOutperform$93.00 ➝ $79.00N/A
2/6/2017CowenSet Price TargetBuy$100.00N/A
1/28/2017William BlairReiterated RatingOutperformN/A
1/26/2017CitigroupBoost Price Target$87.00N/A
1/25/2017CitigroupReiterated RatingBuy$90.00 ➝ $87.00N/A
1/24/2017Needham & Company LLCReiterated RatingHoldN/A
1/24/2017CowenReiterated RatingOutperform$100.00N/A
1/18/2017CowenSet Price TargetBuy$100.00N/A
(Data available from 1/17/2017 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 4 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 3 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
  • 4 very positive mentions
  • 29 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
  • 1 very positive mentions
  • 10 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
  • 8 very positive mentions
  • 14 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
  • 11 very positive mentions
  • 50 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
  • 11 very positive mentions
  • 23 positive mentions
  • 7 negative mentions
  • 4 very negative mentions
  • 11 very positive mentions
  • 23 positive mentions
  • 4 negative mentions
  • 3 very negative mentions

Current Sentiment

  • 11 very positive mentions
  • 23 positive mentions
  • 4 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

Gilead Sciences logo
Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Read More

Today's Range

Now: $71.77
Low: $71.16
High: $72.14

50 Day Range

MA: $70.49
Low: $65.97
High: $73.64

52 Week Range

Now: $71.77
Low: $61.39
High: $74.12


8,344,700 shs

Average Volume

7,725,060 shs

Market Capitalization

$90.03 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Gilead Sciences?

The following equities research analysts have issued stock ratings on Gilead Sciences in the last year: BMO Capital Markets, Credit Suisse Group AG, Evercore ISI, Jefferies Financial Group Inc., Morgan Stanley, Needham & Company LLC, Oppenheimer Holdings Inc., Piper Sandler, Redburn Partners, Royal Bank of Canada, Sanford C. Bernstein, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for GILD.

What is the current price target for Gilead Sciences?

11 Wall Street analysts have set twelve-month price targets for Gilead Sciences in the last year. Their average twelve-month price target is $79.36, suggesting a possible upside of 10.6%. Oppenheimer Holdings Inc. has the highest price target set, predicting GILD will reach $100.00 in the next twelve months. Credit Suisse Group AG has the lowest price target set, forecasting a price of $66.00 for Gilead Sciences in the next year.
View the latest price targets for GILD.

What is the current consensus analyst rating for Gilead Sciences?

Gilead Sciences currently has 6 hold ratings and 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GILD will outperform the market and that investors should add to their positions of Gilead Sciences.
View the latest ratings for GILD.

What other companies compete with Gilead Sciences?

How do I contact Gilead Sciences' investor relations team?

Gilead Sciences' physical mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company's listed phone number is (650) 574-3000 and its investor relations email address is [email protected] The official website for Gilead Sciences is